Steven Cohen Caribou Biosciences, Inc. Transaction History

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 289,739 shares of CRBU stock, worth $834,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,739

Previous 228,885 26.59%

Holding current value

$834,448

Previous $208,000 75.48%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.73 - $1.42 $44,423 - $86,412	60,854 Added 26.59%	289,739 $365,000
Q1 2025 May 15, 2025	SELL	$0.88 - $1.88 $700,571 - $1.5 Million	-796,104 Reduced 77.67%	228,885 $208,000
Q4 2024 Feb 14, 2025	SELL	$1.59 - $2.79 $1.76 Million - $3.09 Million	-1,106,429 Reduced 51.91%	1,024,989 $1.63 Million
Q3 2024 Nov 14, 2024	SELL	$1.56 - $2.73 $330,910 - $579,093	-212,122 Reduced 9.05%	2,131,418 $4.16 Million
Q2 2024 Aug 14, 2024	SELL	$1.62 - $5.05 $2.01 Million - $6.27 Million	-1,241,478 Reduced 34.63%	2,343,540 $3.84 Million
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $306,754 - $525,682	63,642 Added 1.81%	3,585,018 $18.4 Million
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $77,123 - $134,643	21,543 Added 0.62%	3,521,376 $20.2 Million
Q3 2023 Nov 14, 2023	BUY	$4.08 - $8.14 $13.1 Million - $26.1 Million	3,210,094 Added 1107.93%	3,499,833 $16.7 Million
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $1.61 Million - $3.19 Million	289,739 New	289,739 $1.82 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $4.56 Million - $8.78 Million	289,739 New	289,739 $6.92 Million

Others Institutions Holding CRBU

# of Institutions

133

Shares Held

43.5M

Call Options Held

25K

Put Options Held

53.2K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $175M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account